Add to ORKGThe Author(s) 2012. This article is published with open access at Springerlink.com Introduction: Sarcoidosis is a systemic granulomatous disease of unknown cause. The management of sarcoidosis remains problematic. Systemic and topical corticosteroids are the mainstay of therapy but may cause unacceptabl
Sarcoidosis and Crohn's disease are systemic granulomatous disorders affecting the lung and the inte...
Etanercept is a soluble receptor fusion protein that inhibits tumor necrosis factor-alpha(TNF-&alpha...
Since the introduction of anti-tumour necrosis factor [TNF] therapy in inflammatory diseases, parado...
Sarcoidosis is a systemic chronic granulomatous disease of unknown etiology. It predominantly involv...
Abstract Background Sarcoidosis is a multisystemic granulomatous disease of unknown origin. It is ch...
Copyright © 2014 Nader Chebib et al. This is an open access article distributed under the Creative C...
Sarcoidosis is a systemic granulomatous disease characterized by the presence of non-caseating granu...
Sarcoidosis is a multisystemic disorder of unknown cause. Diagnosis is established when clinical and...
Omalizumab, a monoclonal anti-immunoglobulin E antibody, has been used as an effective treatment for...
Sarcoidosis is a granulomatous disease whose outcome varies from spontaneous remission to chronic re...
International audienceOBJECTIVE: TNF blockers have been recently evaluated for treating refractory s...
Sarcoidosis is a granulomatous disease whose outcome varies from spontaneous remission to chronic re...
Sarcoidosis is a multisystem disorder of unknown cause with a highly variable course. Corticosteroid...
Objectives: to report 2 cases of sarcoidosis developed during treatment with anti-TNFalfa antagonist...
Item does not contain fulltextPURPOSE OF REVIEW: Sarcoidosis is a systemic disease characterized by ...
Sarcoidosis and Crohn's disease are systemic granulomatous disorders affecting the lung and the inte...
Etanercept is a soluble receptor fusion protein that inhibits tumor necrosis factor-alpha(TNF-&alpha...
Since the introduction of anti-tumour necrosis factor [TNF] therapy in inflammatory diseases, parado...
Sarcoidosis is a systemic chronic granulomatous disease of unknown etiology. It predominantly involv...
Abstract Background Sarcoidosis is a multisystemic granulomatous disease of unknown origin. It is ch...
Copyright © 2014 Nader Chebib et al. This is an open access article distributed under the Creative C...
Sarcoidosis is a systemic granulomatous disease characterized by the presence of non-caseating granu...
Sarcoidosis is a multisystemic disorder of unknown cause. Diagnosis is established when clinical and...
Omalizumab, a monoclonal anti-immunoglobulin E antibody, has been used as an effective treatment for...
Sarcoidosis is a granulomatous disease whose outcome varies from spontaneous remission to chronic re...
International audienceOBJECTIVE: TNF blockers have been recently evaluated for treating refractory s...
Sarcoidosis is a granulomatous disease whose outcome varies from spontaneous remission to chronic re...
Sarcoidosis is a multisystem disorder of unknown cause with a highly variable course. Corticosteroid...
Objectives: to report 2 cases of sarcoidosis developed during treatment with anti-TNFalfa antagonist...
Item does not contain fulltextPURPOSE OF REVIEW: Sarcoidosis is a systemic disease characterized by ...
Sarcoidosis and Crohn's disease are systemic granulomatous disorders affecting the lung and the inte...
Etanercept is a soluble receptor fusion protein that inhibits tumor necrosis factor-alpha(TNF-&alpha...
Since the introduction of anti-tumour necrosis factor [TNF] therapy in inflammatory diseases, parado...